CalciMedica (NASDAQ:CALC) Shares to Reverse Split on Monday, August 31st

CalciMedica Inc. (NASDAQ:CALC) shares are going to reverse split on Monday, August 31st. The 1-5 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 30th.

CalciMedica Trading Down 20.0%

Shares of CALC traded down $0.12 during mid-day trading on Thursday, reaching $0.47. The company had a trading volume of 1,490,454 shares, compared to its average volume of 335,053. CalciMedica has a fifty-two week low of $0.46 and a fifty-two week high of $7.20. The firm has a fifty day simple moving average of $0.75 and a 200-day simple moving average of $0.70. The stock has a market cap of $16.05 million, a price-to-earnings ratio of -0.35 and a beta of 0.91. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67.

CalciMedica (NASDAQ:CALC) last posted its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17). On average, sell-side analysts anticipate that CalciMedica will post -1.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CALC has been the topic of several recent analyst reports. Guggenheim started coverage on CalciMedica in a research report on Thursday, August 20th. They set a “buy” rating on the stock. Wall Street Zen upgraded CalciMedica to a “sell” rating in a research note on Saturday, August 22nd. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Weiss Ratings cut shares of CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.00.

Insider Buying and Selling at CalciMedica

In other CalciMedica news, Director Fred A. Middleton bought 248,972 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was bought at an average price of $0.80 per share, for a total transaction of $199,177.60. Following the transaction, the director owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. The trade was a 30.57% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 28.25% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CalciMedica

Large investors have recently made changes to their positions in the stock. 180 Wealth Advisors LLC lifted its stake in shares of CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after purchasing an additional 94,650 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of CalciMedica during the fourth quarter worth approximately $506,000. PVG Asset Management Corp bought a new stake in shares of CalciMedica during the fourth quarter valued at approximately $302,000. Renaissance Technologies LLC raised its stake in shares of CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after acquiring an additional 39,775 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the period.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.